CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down
02.10.19|Tzally Greenberg
Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication